{"disease":{"id":"immune-thrombocytopenia","name":"Immune thrombocytopenia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":9},"drugs":{"marketed":[{"drug_id":"efgartigimod","indication_name":"Immune thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Efgartigimod","company_name":"M. Peter Marinkovich","drug_phase":"marketed","molecular_target":"FcRn","drug_class":"Endoglycosidase [EPC]","quality_score":58,"revenue":"2500","mechanism":"Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability."},{"drug_id":"efgartigimod-alfa","indication_name":"Immune thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyvgart","generic_name":"EFGARTIGIMOD ALFA","company_name":"Argenx Bv","drug_phase":"marketed","molecular_target":"IgG receptor FcRn large subunit p51","drug_class":"Endoglycosidase [EPC]","quality_score":70,"revenue":"2500","mechanism":"Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream."},{"drug_id":"rilzabrutinib","indication_name":"persistent or chronic immune thrombocytopenia (ITP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wayrilz","generic_name":"RILZABRUTINIB","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Wayrilz works by blocking a specific enzyme that helps platelet-destroying immune cells function."},{"drug_id":"fostamatinib","indication_name":"Immune thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05345561","title":"Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":14390,"lead_sponsor_name":"Rallybio","has_results":false},{"nct_id":"NCT03820960","title":"Risk Factors for Thrombosis in Immune Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":10039,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT04067375","title":"Towards Routine HPA-screening In Pregnancy to Prevent FNAIT","phase":"","overall_status":"COMPLETED","enrollment_count":3660,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05937828","title":"OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07068425","title":"Longitudinal Observational Study on Immune Thrombocytopenia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05333861","title":"An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1150,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05522465","title":"Short-course High-dose Prednisone and Dexamethasone in Children With ITP","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":608,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT05520892","title":"Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT06556888","title":"Observatory of Immunological Thrombopenic Purpura in the Brest Region","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07070193","title":"Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07268898","title":"National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05861297","title":"Immune Thrombocytopenia Management in Adults","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":467,"lead_sponsor_name":"Nahda University","has_results":false},{"nct_id":"NCT05095896","title":"The Serum Lipid Profiles in ITP: a Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":457,"lead_sponsor_name":"Ming Hou","has_results":false},{"nct_id":"NCT07298733","title":"The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT06408324","title":"Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"European Research Consortium on ITP","has_results":false},{"nct_id":"NCT05029635","title":"Phase III Study on HMPL-523 for Treatment of ITP","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":272,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT04968899","title":"IgIV Plus Prednisone vs High-dose Dexamethasone for ITP","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":272,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05459649","title":"Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":253,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04562766","title":"Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":232,"lead_sponsor_name":"Principia Biopharma, a Sanofi Company","has_results":true},{"nct_id":"NCT05494307","title":"The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":228,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05653349","title":"Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04518475","title":"Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":224,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03201848","title":"The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Qidong Gaitianli Medicines Co., Ltd","has_results":false},{"nct_id":"NCT05621330","title":"Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04687072","title":"A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT02279173","title":"Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03460808","title":"The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03252457","title":"Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT03443570","title":"Rituximab Combining Bortezomib Versus Rituximab in Management of ITP","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT05654766","title":"Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","has_results":false},{"nct_id":"NCT04943042","title":"An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT06004856","title":"Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":195,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04812925","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT03304288","title":"The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":168,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05718856","title":"TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":166,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07421167","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":164,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07175493","title":"A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT05583838","title":"A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05653219","title":"A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07189910","title":"Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05369377","title":"Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07587723","title":"A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05369364","title":"The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06723106","title":"Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT06371417","title":"Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT07196163","title":"An Exploratory Study of Golidocitinib in Adult Patients With ITP","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":138,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04217148","title":"The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07065968","title":"The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07064889","title":"The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Peking University People's Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}